156 related articles for article (PubMed ID: 38480922)
21. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
22. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
23. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
24. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
Burger MC; Forster MT; Romanski A; Straßheimer F; Macas J; Zeiner PS; Steidl E; Herkt S; Weber KJ; Schupp J; Lun JH; Strecker MI; Wlotzka K; Cakmak P; Opitz C; George R; Mildenberger IC; Nowakowska P; Zhang C; Röder J; Müller E; Ihrig K; Langen KJ; Rieger MA; Herrmann E; Bonig H; Harter PN; Reiss Y; Hattingen E; Rödel F; Plate KH; Tonn T; Senft C; Steinbach JP; Wels WS
Neuro Oncol; 2023 Nov; 25(11):2058-2071. PubMed ID: 37148198
[TBL] [Abstract][Full Text] [Related]
25. Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma.
Wang S; O'Rourke DM; Chawla S; Verma G; Nasrallah MP; Morrissette JJD; Plesa G; June CH; Brem S; Maloney E; Desai A; Wolf RL; Poptani H; Mohan S
Br J Cancer; 2019 Jan; 120(1):54-56. PubMed ID: 30478409
[TBL] [Abstract][Full Text] [Related]
26. Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients.
Guo JX; Wu CX; Wang PF; Li ZJ; Han S; Jin W; Lin ZX
Front Biosci (Landmark Ed); 2019 Jun; 24(6):1158-1166. PubMed ID: 31136972
[TBL] [Abstract][Full Text] [Related]
27. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
28. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
29. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
[TBL] [Abstract][Full Text] [Related]
31. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
[TBL] [Abstract][Full Text] [Related]
32. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
Brown CE; Rodriguez A; Palmer J; Ostberg JR; Naranjo A; Wagner JR; Aguilar B; Starr R; Weng L; Synold TW; Tran V; Wang S; Reik A; D'Apuzzo M; Ressler JA; Zhou Y; Mendel M; Gregory PD; Holmes MC; Tang WW; Forman SJ; Jensen MC; Badie B
Neuro Oncol; 2022 Aug; 24(8):1318-1330. PubMed ID: 35100373
[TBL] [Abstract][Full Text] [Related]
33. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
[TBL] [Abstract][Full Text] [Related]
34. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
[TBL] [Abstract][Full Text] [Related]
35. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
Yin Y; Rodriguez JL; Li N; Thokala R; Nasrallah MP; Hu L; Zhang L; Zhang JV; Logun MT; Kainth D; Haddad L; Zhao Y; Wu T; Johns EX; Long Y; Liang H; Qi J; Zhang X; Binder ZA; Lin Z; O'Rourke DM
Mol Ther; 2022 Jul; 30(7):2537-2553. PubMed ID: 35570396
[TBL] [Abstract][Full Text] [Related]
36. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
38. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
39. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
40. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
